

Active substances set

Search phrase: idelalisib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Idelalisib

Idelalisib is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

 **NO REIMBURSEMENT**
 **ESMO**

Chronic lymphoid leukemia

Idelalisib

Idelalisib is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): - who have received at least one prior therapy, or - as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

 **NO REIMBURSEMENT**
 **ESMO**